Small Bowel Amyloidosis

被引：12

作者：

Bansal R. ^{[1
]}

Syed U. ^{[1
]}

Walfish J. ^{[2
]}

Aron J. ^{[1
]}

Walfish A. ^{[1
]}

机构：

[1] Division of Gastroenterology and Hepatology, Elmhurst Hospital Center, Icahn School of Medicine at Mount Sinai, Room D3-24D, 79-01 Broadway, Elmhurst, 11373, NY

[2] Department of Medicine, NYU School of Medicine, NYU Langone Health, 101 Broadway, Suite 301, Brooklyn, 11249, NY

来源：

Current Gastroenterology Reports | 2018年 / 20卷 / 3期

关键词：

Amyloidosis; Gastrointestinal; Small bowel;

D O I：

10.1007/s11894-018-0616-y

中图分类号：

学科分类号：

摘要：

Purpose of Review: The goal of this paper is to review the literature on small bowel amyloidosis. Our review focuses on the underlying etiology, histopathology, clinical features, endoscopic and radiologic findings, and the mainstay of management. Recent Findings: The latest research shows changing epidemiological trends of different types of amyloidosis. It also reveals a better understanding of its pathophysiology and shows improvement in treatment outcomes. Summary: Amyloidosis is a group of diseases of multiple etiologies and clinical presentations. It is characterized by pathological deposition of insoluble fibrillar proteins within various organs leading to disruption of their structure and function. The classification of amyloidosis includes primary, secondary, dialysis-related, senile, and hereditary. Amyloidosis can be systemic or localized. The incidence of AA amyloidosis is declining in frequency. If the gastrointestinal (GI) tract is involved, the small intestine is the most commonly affected site. Overall, outcomes among patients with newly diagnosed amyloidosis have improved. This article focuses on small bowel amyloidosis. © 2018, Springer Science+Business Media, LLC, part of Springer Nature.

引用

共 56 条

[1]

Merlini G., Bellotti V., Molecular mechanisms of amyloidosis, N Engl J Med, 349, 6, pp. 583-596, (2003)

[2]

Sattianayagam P.T., Hawkins P.N., Gillmore J.D., Systemic amyloidosis and the gastrointestinal tract, Nat Rev Gastroenterol Hepatol, 6, 10, pp. 608-617, (2009)

[3]

Sipe J.D., Benson M.D., Buxbaum J.N., Ikeda S., Merlini G., Saraiva M.J., Et al., Nomenclature 2014: amyloid fibril proteins and clinical classification of the amyloidosis, Amyloid, 21, 4, pp. 221-224, (2014)

[4]

Cowan A.J., Skinner M., Seldin D.C., Berk J.L., Lichtenstein D.R., O'Hara C.J., Doros G., Sanchorawala V., Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience, Haematologica, 98, 1, pp. 141-146, (2013)

[5]

Freudenthaler S., Hegenbart U., Schonland S., Behrens H.M., Kruger S., Rocken C., Amyloid in biopsies of the gastrointestinal tract—a retrospective observational study on 542 patients, Virchows Arch, 468, 5, pp. 569-577, (2016)

[6]

Lane T., Pinney J.H., Gilbertson J.A., Hutt D.F., Rowczenio D.M., Mahmood S., Sachchithanantham S., Fontana M., Youngstein T., Quarta C.C., Wechalekar A.D., Gillmore J.D., Hawkins P.N., Lachmann H.J., Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre, Amyloid, 24, 3, pp. 162-166, (2017)

[7]

Tosca Cuquerella J., Bosca-Watts M.M., Anton Ausejo R., Tejedor Alonso S., Mora De Miguel F., Minguez Perez M., Amyloidosis in inflammatory bowel disease: a systematic review of epidemiology, clinical features, and treatment, J Crohns Colitis, 10, 10, pp. 1245-1253, (2016)

[8]

Sharma P., Aguilar R., Siddiqui O.A., Nader M.A., Secondary systemic amyloidosis in inflammatory bowel disease: a nationwide analysis, Ann Gastroenterol, 30, 5, pp. 504-511, (2017)

[9]

Werther J.L., Schapira A., Rubinstein O., Janowitz H.D., Amyloidosis in regional enteritis. A report of five cases, Am J Med, 29, 3, pp. 416-423, (1960)

[10]

Greenstein A.J., Sachar D.B., Panday A.K., Dikman S.H., Meyers S., Heimann T., Gumaste V., Werther J.L., Janowitz H.D., Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients, Medicine (Baltimore), 71, 5, pp. 261-270, (1992)

← 1 2 3 4 5 6 →